Cardiff Oncology, Inc.

Equities

CRDF

US14147L1089

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
4.18 ^USD	+0.24%		-7.11%	+182.43%

Apr. 08	Cardiff Oncology Presents Novel Preclinical Data At Aacr Annual Meeting 2024 That Supports Ongoing First-Line Ras-Mutated Mcrc Clinical Study	CI
Mar. 06	HC Wainwright Adjusts Price Target on Cardiff Oncology to $14 From $12, Keeps Buy Rating	MT

TROVAGENE, INC. : Other Events (form 8-K)

January 21, 2020 at 10:11 am EST

Item 8.01 Other Events.

On January 21, 2020, Trovagene, Inc. (the "Company") issued a press release announcing that a poster featuring safety and efficacy data from its Phase 1b/2 study in metastatic KRAS-mutated colorectal cancer (mCRC), will be presented on Saturday, January 25th, 2020 at the American Society for Clinical Oncology (ASCO) 2020 Gastrointestinal Cancers Symposium in San Francisco. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

Latest news about Cardiff Oncology, Inc.

Cardiff Oncology Presents Novel Preclinical Data At Aacr Annual Meeting 2024 That Supports Ongoing First-Line Ras-Mutated Mcrc Clinical Study	Apr. 08	CI
HC Wainwright Adjusts Price Target on Cardiff Oncology to $14 From $12, Keeps Buy Rating	Mar. 06	MT
Sector Update: Health Care Stocks Rising Late Afternoon	Mar. 01	MT
Sector Update: Health Care	Mar. 01	MT
Cardiff Oncology Shares Jump, Discontinued Cancer Treatment Trial Shows Efficacy	Mar. 01	MT
Piper Sandler Adjusts Price Target on Cardiff Oncology to $7 From $5, Maintains Overweight Rating	Mar. 01	MT
Transcript : Cardiff Oncology, Inc., Q4 2023 Earnings Call, Feb 29, 2024	Feb. 29
Cardiff Oncology, Inc. Announces First Patient Dosed in Randomized First-Line RAS-Mutated Metastatic Colorectal Cancer Trial (CRDF-004)	Feb. 29	CI
Cardiff Oncology, Inc. Provides Clinical Update on Phase 2 Randomized Second-Line ONSEMBLE Trial in Patients with RAS-Mutated mCRC	Feb. 29	CI
Cardiff Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Transcript : Cardiff Oncology, Inc., Q3 2023 Earnings Call, Nov 02, 2023	Nov. 02
Cardiff Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Top Premarket Gainers	23-09-27	MT
North American Morning Briefing : Stock Futures Helped by Retreating Bond Yields	23-09-27	DJ
Cardiff Oncology Reports 'Positive' Results From Onvansertib Monotherapy Trial for Pancreatic, Small Cell Lung Cancers	23-09-26	MT
Transcript : Cardiff Oncology, Inc. - Special Call	23-09-26
Cardiff Oncology, Inc. Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, Including Single-Agent Activity from Onvansertib Monotherapy	23-09-26	CI
Cardiff Oncology, Inc.(NasdaqCM:CRDF) dropped from S&P Global BMI Index	23-09-18	CI
North American Morning Briefing : Stock Futures -2-	23-08-16	DJ
HC Wainwright Adjusts Price Target on Cardiff Oncology to $12 From $13, Maintains Buy Rating	23-08-11	MT
Cardiff Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Sector Update: Health Care Stocks Gaining Late Tuesday	23-08-08	MT
Sector Update: Health Care	23-08-08	MT
Top Midday Gainers	23-08-08	MT
Cardiff Oncology Shares Jump; Company Sets Lead Program in First-Line Metastatic Colorectal Cancer	23-08-08	MT

Chart Cardiff Oncology, Inc.

Duration

Period

More charts

Company Profile

Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. It has five ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, one trial (CRDF-001) in second-line treatment in patients with mPDAC, and three investigator-initiated trials in first line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.

Sector

Biotechnology & Medical Research

Calendar

2024-05-01 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Cardiff Oncology, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.18 USD

Average target price

9.893 USD

Spread / Average Target

+136.68%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CARDIFF ONCOLOGY, INC.	+182.43%	187M
IQVIA HOLDINGS INC.	+4.09%	43.84B
LONZA GROUP AG	+46.34%	41.25B
MODERNA, INC.	+9.45%	41.68B
CELLTRION, INC.	-10.92%	27.04B
ICON PUBLIC LIMITED COMPANY	+9.32%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-24.87%	18.18B
MEDPACE HOLDINGS, INC.	+29.70%	12.29B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	12.29B
UNITED THERAPEUTICS CORPORATION	+7.78%	11.15B

Other Biotechnology & Medical Research